药物诱导性勃起功能障碍:使用FDA不良事件报告系统数据库的现实世界药监测研究
Dongxuan Li1, Liyang Dai2, Jun Zhu1
1Department of Pharmacy, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Expert opinion on drug safety
|August 23, 2024
概括
这项研究使用FDA数据确定了734种与勃起功能障碍 (ED) 相关的药物. 费纳斯特和泌尿器官药物显示了药物诱导性ED的最高报告频率和信号强度.
科学领域:
- 药物监督 药物监督 药物监督
- 药品安全 药品安全
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 药物诱导勃起功能障碍 (ED) 的综合风险数据有限.
- 现有的数据缺乏与各种药物相关的ED风险的定量和比较分析.
研究的目的:
- 为药物诱导的ED提供全面的定量和比较风险数据.
- 确定与ED相关的潜在罪祸首药物和药物类别.
主要方法:
- 从FDA不良事件报告系统 (FAERS) 数据库 (2004-2023) 中分析了20098份ED报告.
- 使用报告几率比率 (ROR) 方法进行不成比例分析.
- 确定了具有ED发生的积极信号的药物.
主要成果:
- 在74个药物类别中,有734种不同的药物与ED有关.
- 费纳斯特具有最高的报告频率和信号强度.
- 209种药物与ED有显著的关系;复合制剂的风险高于单个活性成分.
结论:
- 这项研究为734种药物提供了综合的定量和比较性ED风险数据.
- 调查结果为监管机构,医疗保健专业人员和药物安全管理提供了宝贵的参考.
- 强调需要仔细考虑药物诱导的ED风险,特别是复合配方.
相关概念视频
Pharmacovigilance
795
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
795
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
138
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
138
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Desensitization and Tachyphylaxis
1.6K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.6K
Dose-Response Relationship: Potency and Efficacy
4.3K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.3K


